Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

December 22, 2020

Study Completion Date

February 2, 2021

Conditions

Metastatic Gastric CancerMetastatic Breast CancerMetastatic Colorectal CancerMetastatic Lung Cancer

Interventions

DRUG

OBI-833/OBI-821

Trial Locations (4)

Tri-Service General Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Medical University Hospital, Taipei

Taipei Medical University Shuang Ho Hospital, New Taipei City